The Institute for Clinical and Economic Review (ICER) is partnering with Aetion to “generate decision-grade real-world evidence,” the drug pricing watchdog announced Monday.
According to a press release, Aetion’s solutions would help ICER discover where it can use RWE to bolster its assessments.
“ICER has long sought data generated outside clinical trials to enhance our understanding of how medical treatments perform in the real world,” ICER CSO Pamela Bradt said in a statement. “Aetion’s rapid-cycle analytics will enable us to quickly generate evidence with the needed rigor and transparency to include in our reviews.”
To read the full press release, click here.